Lipocine (LPCN) AI Stock Analysis

• Market Cap: $53.21M
• Dividend Yield: N/A
• Average Volume (3M): 105.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: -44.31%
• EPS Growth: -34.17%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.43
• Shares Outstanding: 7,299,687
• 10 Day Avg. Volume: 125,876
• 30 Day Avg. Volume: 105,839
• PEG Ratio: <0.01
• Price to Book (P/B): 3.02
• Price to Sales (P/S): 22.14
• P/FCF Ratio: -4.48
• Enterprise Value/Market Cap: 0.70
• Enterprise Value/Revenue: 18.91
• Enterprise Value/Gross Profit: -213.50
• Enterprise Value/Ebitda: -3.63
• 1Y Price Target: $13.00
• Price Target Upside: 345.21% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -1.81
• Revenue Forecast (FY): $625.00K

• Rating: 45 Neutral
• Price Target: $7.00 ▲(139.73% Upside)
• Action: Reiterated Date: 03/10/26
• Date: Action: Reiterated 03/10/26

Overall score is held down primarily by weak/volatile financial performance and poor cash-flow quality, alongside bearish technical momentum. Positive Phase 3 trial progress provides a meaningful offset, but valuation support is limited given ongoing losses and a negative P/E.

Positive Factors

Phase 3 completion & NDA path

Completing a pivotal Phase 3 and targeting a 505(b)(2) NDA materially de-risks LPCN 1154 versus earlier-stage assets. A clear regulatory path improves partner and investor visibility, supports potential licensing or commercialization deals, and could unlock milestone and royalty revenue streams if approved.

Proprietary oral lipid-based delivery

Owning lipid-based oral formulation technology is a durable competitive asset: it enables oral versions of therapies that are otherwise IV-only, improves patient access and adherence, and creates a platform that can be licensed across endocrine and CNS indications for recurring partner revenue opportunities.

Low leverage / zero reported debt

A debt-free balance sheet reduces immediate refinancing and interest risks, giving Lipocine structural financial flexibility to pursue regulatory milestones or partner negotiations. Low leverage preserves options for non-dilutive deals or orderly capital raises versus distressed borrowing under stress.

Negative Factors

Sustained negative cash generation

Persistent negative operating and free cash flow indicates the business is not self-funding and will require external capital to advance programs. This structural cash burn increases dilution risk, pressures management to secure deals or equity, and constrains long-term investment without partner funding.

Volatile revenue and recurrent losses

Sharp revenue declines and uneven profitability signal an unstable earnings base and limited operating leverage. Such volatility reduces predictability for partners and lenders, complicates planning for commercialization investment, and weakens long-term financial resilience absent new revenue streams.

Business model dependent on partnerships

Reliance on licensing and milestone-driven revenue is structurally risky: monetization hinges on successful trials, regulatory approval, and favorable partner terms. If programs underperform or licensing markets are weak, expected revenue streams may not materialize, leaving the company financially exposed.

Lipocine Business Overview & Revenue Model

Company Description

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

How the Company Makes Money

Lipocine’s business model is centered on advancing proprietary drug candidates through clinical development and then seeking to generate revenue primarily via (a) licensing or partnering its drug candidates and/or formulation technology to larger pharmaceutical companies, and (b) commercialization economics if a partnered or internally developed product reaches the market (e.g., milestone payments and royalties). The extent, timing, and magnitude of such revenues are dependent on successful clinical trial outcomes, regulatory approvals, and the terms of any collaboration or licensing agreements. Specific, current details on material revenue streams, commercial products, or active partnership payment structures are null.

Lipocine Financial Statement Overview

Summary

Financial profile is weak and volatile: 2025 revenue fell sharply (~54% vs. 2024) and results reverted to a sizable net loss. Cash generation is a major concern with negative operating/free cash flow in most years and no clear evidence of durable improvement, partly offset by a low-leverage balance sheet (zero reported debt in 2022–2025) but with materially declining equity.

Income Statement

Results are highly volatile and currently weak. Annual revenue fell sharply in 2025 (down ~54% vs. 2024), and the company swung from near break-even net income in 2024 to a sizable loss in 2025. Profitability has been inconsistent across the period, with multiple years of large net losses (2020, 2022, 2023, 2025), which signals an uneven earnings base and limited operating leverage.

Balance Sheet

The balance sheet looks relatively clean from a leverage standpoint: total debt is reported at 0 in 2022–2025 (and was modest in 2021/2020), reducing refinancing and interest-burden risk. However, equity has declined materially from 2022 to 2025 (roughly $35.6M to $14.5M), consistent with ongoing losses and cash burn, and total assets have also stepped down—highlighting shrinking financial flexibility despite low leverage.

Cash Flow

Cash generation is a key weakness. Operating cash flow and free cash flow have been negative in most years shown (notably large outflows in 2020–2023), indicating the business has not been self-funding. 2025 shows operating and free cash flow at 0 with free cash flow growth of -100%, which—combined with the net loss—does not demonstrate a durable improvement in cash conversion or funding needs.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.98M	11.20M	-2.85M	500.00K	16.14M
Gross Profit	1.92M	11.20M	-13.03M	-8.06M	8.48M
EBITDA	-10.31M	-1.11M	-17.90M	-10.72M	-430.53K
Net Income	-9.63M	8.35K	-16.35M	-10.76M	-634.40K
Balance Sheet
Total Assets	17.01M	22.51M	23.00M	37.54M	52.48M
Cash, Cash Equivalents and Short-Term Investments	14.93M	21.63M	22.04M	32.53M	44.62M
Total Debt	0.00	0.00	0.00	0.00	2.31M
Total Liabilities	2.53M	1.51M	2.63M	1.91M	6.91M
Stockholders Equity	14.48M	21.00M	20.37M	35.63M	45.57M
Cash Flow
Free Cash Flow	-9.76M	-1.31M	-11.88M	-12.10M	-4.42M
Operating Cash Flow	-9.76M	-1.22M	-11.87M	-11.97M	-4.41M
Investing Cash Flow	5.89M	2.45M	13.08M	14.29M	-43.78M
Financing Cash Flow	2.87M	209.34K	404.57K	-2.13M	26.92M

Lipocine Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.92
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LPCN, the sentiment is Neutral. The current price of 2.92 is below the 20-day moving average (MA) of 8.80, below the 50-day MA of 9.00, and below the 200-day MA of 4.65, indicating a neutral trend. The MACD of -0.30 indicates Positive momentum. The RSI at 37.66 is Neutral, neither overbought nor oversold. The STOCH value of 5.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LPCN.

Lipocine Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IBIO	51 Neutral	$82.56M	-5.32	-71.26%	―	185.71%	79.03%
SNSE	51 Neutral	$37.71M	-0.65	-80.00%	―	―	9.63%
LPCN	45 Neutral	$53.21M	-4.54	-59.29%	―	-44.31%	-34.17%
BCDA	45 Neutral	$13.48M	-1.37	-317.47%	―	-100.00%	58.50%
PULM	43 Neutral	$7.82M	-1.58	-79.47%	―	-99.97%	35.59%

Lipocine Corporate Events

Lipocine Files Prospectus to Enable $50M Stock Offering

On April 26, 2024, Lipocine Inc. entered into a sales agreement with A.G.P./Alliance Global Partners to offer and sell shares of its common stock from time to time through the sales agent. On February 26, 2026, the company filed a prospectus supplement covering up to $50 million of common stock to be sold under this arrangement, providing Lipocine with a mechanism to raise additional equity capital as needed.

The most recent analyst rating on (LPCN) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.

Lipocine Completes Phase 3 Trial for Postpartum Depression

On February 18, 2026, Lipocine announced that the last patient completed the final visit in its pivotal randomized, double-blind, placebo-controlled Phase 3 trial of LPCN 1154, an oral formulation of brexanolone, for severe postpartum depression. The 90‑patient study, conducted at 19 U.S. sites in an outpatient setting without required medical monitoring, reported a favorable safety profile with only mild to moderate nervous system adverse events and no drug-related serious events or treatment discontinuations.

The trial design closely mirrored prior registrational studies for intravenous brexanolone that supported approval of Zulresso for postpartum depression, including similar patient severity, treatment duration, and primary endpoint measuring change in HAM-D score at Hour 60. Lipocine expects Phase 3 data to support a 505(b)(2) NDA filing for LPCN 1154 in 2026, highlighting the drug’s potential to offer rapid symptom relief, short 48‑hour at‑home dosing, and improved tolerability, which could strengthen the company’s position in the PPD market and address key access and convenience limitations of existing therapies.

The most recent analyst rating on (LPCN) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.

Lipocine Updates Investor Presentation to Reflect Latest Strategy

Lipocine has updated the corporate presentation it uses in meetings with investors, analysts and other stakeholders, and formally filed the revised materials for public access. The refreshed deck is intended to align the company’s external communications with its latest information and may shape how market participants assess Lipocine’s outlook and strategy.

The most recent analyst rating on (LPCN) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.

Lipocine Completes Phase 3 Enrollment for Postpartum Depression Drug

On January 20, 2026, Lipocine announced it has completed enrollment and dosing of 90 patients in its Phase 3 clinical trial of LPCN 1154, an oral formulation of brexanolone, for the treatment of postpartum depression, with the candidate showing a favorable safety profile to date and no drug-related serious adverse events or treatment discontinuations. The pivotal, randomized, double-blind outpatient study in women with severe postpartum depression is intended to support a planned 505(b)(2) NDA submission in 2026, positioning LPCN 1154 as a potential first-line, at-home, rapid-acting treatment option in an area where current therapies have slow onset and tolerability limitations, and underscoring Lipocine’s strategic focus on high-need neuropsychiatric indications.

The most recent analyst rating on (LPCN) stock is a Buy with a $12.50 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.

Lipocine updates investor presentation and corporate materials

Lipocine reported that it has updated the corporate presentation it uses in discussions with investors, analysts and other stakeholders. The refreshed materials, which have been formally filed, are intended to support the company’s ongoing investor relations efforts and provide the market with its latest strategic and operational information, though no additional operational or financial details were disclosed in the announcement.

The most recent analyst rating on (LPCN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.

Lipocine Advances Phase 3 Postpartum Depression Drug Trial

On January 12, 2026, Lipocine reported that an independent Data Safety Monitoring Board completed its second planned interim safety review of the company’s Phase 3 trial of LPCN 1154, an oral brexanolone candidate for rapid treatment of postpartum depression, and recommended the study continue without modification. The review, based on safety data from 82 randomized participants, found no drug-related serious adverse events, no excessive sedation, no loss of consciousness, and no treatment discontinuations, with only one dose reduction due to an adverse event, and the trial has stopped screening new participants while continuing to enroll eligible women in an outpatient setting without required medical monitoring. The company said it remains on track to report topline safety and efficacy data early in the second quarter of 2026, with the Phase 3 results expected to support a 505(b)(2) new drug application later that year, underscoring LPCN 1154’s potential to become a first-line, convenient at-home therapy that could shift the treatment paradigm in postpartum depression if ultimately approved.

The most recent analyst rating on (LPCN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.